Author： Chapman R.W. Schilling A. Ng K. Nardo C. Kreutner W. Young S.
Publisher： Academic Press
ISSN： 1094-5539
Source： Pulmonary Pharmacology & Therapeutics, Vol.12, Iss.4, 1999-08, pp. : 261-266
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
SCH 206272: a potent, orally active tachykinin NK 1 , NK 2 , and NK 3 receptor antagonist
By Anthes J.C. Chapman R.W. Richard C. Eckel S. Corboz M. Hey J.A. Fernandez X. Greenfeder S. McLeod R. Sehring S. Rizzo C. Crawley Y. Shih N.-Y. Piwinski J. Reichard G. Ting P. Carruthers N. Cuss F.M. Billah M. Kreutner W. Egan R.W.
European Journal of Pharmacology, Vol. 450, Iss. 2, 2002-08 ,pp. :
Access to resources
Recommend
NK 1 (substance P) receptor antagonists - why are they not analgesic in humans?
By Hill R.
Trends in Pharmacological Sciences, Vol. 21, Iss. 7, 2000-07 ,pp. :
NK 1 receptor antagonists - are they really without effect in the pain clinic?
Trends in Pharmacological Sciences, Vol. 21, Iss. 12, 2000-12 ,pp. :
A New Frontier in the Treatment of Cancer: NK-1 Receptor Antagonists
Current Medicinal Chemistry, Vol. 17, Iss. 6, 2010-02 ,pp. :